Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

"Diffusible-PEG-lipid stabilized plasmid lipid particles".

Ian MacLachlan1, Pieter Cullis

  • 1Protiva Biotherapeutics Incorporated, Burnaby, BC, Canada V5G 4Y1.

Advances in Genetics
|October 26, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Age-Associated Immune Senescence via Nanoparticle-Based Metabolic Reprogramming.

ACS nano·2026
Same author

RNA lipid nanoparticles stabilized during nebulization through excipient selection.

Nanoscale advances·2025
Same author

Quantitative Visualization of Lipid Nanoparticle Fusion as a Function of Formulation and Process Parameters.

ACS nano·2024
Same author

Exploring Mechanisms of Lipid Nanoparticle-Mucus Interactions in Healthy and Cystic Fibrosis Conditions.

Advanced healthcare materials·2024
Same author

Comment on "Recent global decline of CO<sub>2</sub> fertilization effects on vegetation photosynthesis".

Science (New York, N.Y.)·2021
Same author

Protective Effect of Edaravone against Cationic Lipid-Mediated Oxidative Stress and Apoptosis.

Biological & pharmaceutical bulletin·2021

Stabilized plasmid lipid particles (SPLP) improve gene delivery by overcoming common issues with viral and non-viral systems. This study compares SPLP manufacturing methods and analyzes their pharmacological properties for enhanced gene therapy.

Area of Science:

  • Biotechnology
  • Gene Therapy
  • Nanomedicine

Background:

  • Viral and non-viral gene transfer methods face systemic delivery challenges.
  • Liposomal drug delivery offers a promising approach to overcome these limitations.
  • First-generation non-viral systems have inherent pharmacological constraints.

Purpose of the Study:

  • To compare two manufacturing methods for stabilized plasmid lipid particles (SPLP): detergent dialysis and spontaneous vesicle formation.
  • To evaluate the pharmacology of SPLP for gene delivery applications.
  • To assess the potential of SPLP in overcoming limitations of traditional gene transfer systems.

Main Methods:

  • Manufacture of SPLP using detergent dialysis.
  • Manufacture of SPLP using spontaneous vesicle formation via ethanol dilution.

Related Experiment Videos

  • Pharmacological assessment using lipid label monitoring and quantitative real-time PCR.

    • Main Results:

    • Comparison of SPLP yield and characteristics between the two manufacturing methods.
    • Demonstration of enhanced accumulation of SPLP at disease sites.
    • Evidence of selective protein expression mediated by SPLP.
    • Characterization of SPLP pharmacokinetics and biodistribution.

    Conclusions:

    • SPLP represent an advanced non-viral gene delivery system with improved pharmacological properties.
    • The choice of manufacturing method can impact SPLP characteristics and performance.
    • SPLP show potential for targeted gene therapy and overcoming systemic delivery barriers.